Hisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation

MT Newswires Live06-27

Zhejiang Hisun Pharmaceutical's (SHA:600267) idarubicin hydrochloride passed the generic drug consistency evaluation of China's National Medical Products Administration, according to the company's disclosure on the Shanghai Stock Exchange.

The pharmaceutical company filed a supplementary application for the evaluation of the drug's quality and efficacy.

The drug is used for the induction of remission of untreated adult acute non-lymphocytic leukemia and it is also a second-line treatment for acute lymphocytic leukemia, the Thursday disclosure added.

Shares of the company dropped more than 2% in recent trade.

Price (RMB): Â¥7.04, Change: Â¥-0.17, Percent Change: -2.36%

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2446309834?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-06-27 15:01","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2446309834","market":"hk","top_or_hot":-1,"title":"Hisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation","media":"MT Newswires Live","content":"<html><body><p> Zhejiang Hisun Pharmaceutical's (SHA:600267) idarubicin hydrochloride passed the generic drug consistency evaluation of China's National Medical Products Administration, according to the company's disclosure on the Shanghai Stock Exchange.</p><p>The pharmaceutical company filed a supplementary application for the evaluation of the drug's quality and efficacy.</p><p>The drug is used for the induction of remission of untreated adult acute non-lymphocytic leukemia and it is also a second-line treatment for acute lymphocytic leukemia, the Thursday disclosure added.</p><p>Shares of the company dropped more than 2% in recent trade.</p><p>Price (RMB): Â¥7.04, Change: Â¥-0.17, Percent Change: -2.36%</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Hisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHisun Pharmaceutical's Leukemia Drug Passes Chinese Drug Regulator's Consistency Evaluation\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-06-27 15:01 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Zhejiang Hisun Pharmaceutical's (SHA:600267) idarubicin hydrochloride passed the generic drug consistency evaluation of China's National Medical Products Administration, according to the company's ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"600267","symbol_name":"海正药业","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2446309834","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2446309834","pubTimestamp":1719471668,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Zhejiang Hisun Pharmaceutical's  idarubicin hydrochloride passed the generic drug consistency evaluation of China's National Medical Products Administration, according to the company's disclosure on the Shanghai Stock Exchange.The pharmaceutical company filed a supplementary application for the evaluation of the drug's quality and efficacy.The drug is used for the induction of remission of untreated adult acute non-lymphocytic leukemia and it is also a second-line treatment for acute lymphocytic leukemia, the Thursday disclosure added.Shares of the company dropped more than 2% in recent trade.Price : 7.04, Change: -0.17, Percent Change: -2.36%","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"600267":"海正药业","BK0188":"融资融券","BK0028":"国家队","BK0060":"抗癌","BK0239":"医药制造"},"translate_title":"海正药业白血病药物通过中国药监一致性评价","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"600267":0.9},"content_text":"Zhejiang Hisun Pharmaceutical's (SHA:600267) idarubicin hydrochloride passed the generic drug consistency evaluation of China's National Medical Products Administration, according to the company's disclosure on the Shanghai Stock Exchange.The pharmaceutical company filed a supplementary application for the evaluation of the drug's quality and efficacy.The drug is used for the induction of remission of untreated adult acute non-lymphocytic leukemia and it is also a second-line treatment for acute lymphocytic leukemia, the Thursday disclosure added.Shares of the company dropped more than 2% in recent trade.Price (RMB): Â¥7.04, Change: Â¥-0.17, Percent Change: -2.36%","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2446309834"}